A Study of LY4226695 in Healthy Participants

Part of paid clinical trials in Anaheim, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07767487
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
22 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4226695 — DRUG
    Administered SC
  • LY4226695 — DRUG
    Administered IV
  • Placebo — DRUG
    Administered SC

Study Details

The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant in Parts A \& D, the study will last about 64 days and will include a stay in the Clinical Research Unit (CRU) lasting at most 7 days. For each participant in Parts B \& C, the study will last about 92 days and will include 5 stays in the CRU with each visit lasting at most 7 days.

Key Dates

First listed
Aug 17, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
148 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4226695 Part A
    Participants will receive LY4226695 or placebo administered subcutaneously (SC)
  • Experimental: LY4226695 Part B
    Participants will receive LY4226695 or placebo administered SC
  • Experimental: LY4226695 Part C
    Participants will receive LY4226695 or placebo administered SC
  • Experimental: LY4226695 Part D
    Participants will receive LY4226695 administered intravenously (IV)

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Day 57 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
CenExel ACTAnaheimCalifornia92801
714-774-7777
Amina Haggag (PRINCIPAL_INVESTIGATOR)

Find similar trials in Anaheim, CA

By research site
CenExel ACT· Anaheim, CA

Related Studies